Bluefin Capital Management’s GSK GSK Stock Holding History

Bluefin Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,768	Closed	-$261K	–	614
2022 Q2	$261K	Buy	4,768 +48	+1%	+$2.65K	0.03%	259
2022 Q1	$257K	Sell	4,720 -2,640	-36%	-$143K	0.02%	294
2021 Q4	$406K	Sell	7,360 -736	-9%	-$38.3K	0.03%	380
2021 Q3	$387K	Buy	+8,096	New	+$407K	0.04%	328
2017 Q3	–	Sell	-11,277	Closed	-$608K	–	525
2017 Q2	$608K	Buy	11,277 +5,949	+112%	+$317K	0.07%	214
2017 Q1	$281K	Buy	5,328 +311	+6%	+$15.8K	0.04%	262
2016 Q4	$241K	Buy	+5,017	New	+$248K	0.01%	305
2016 Q3	–	Sell	-4,870	Closed	-$264K	–	495
2016 Q2	$264K	Buy	+4,870	New	+$257K	0.03%	269
2016 Q1	–	Sell	-39,803	Closed	-$2.01M	–	583
2015 Q4	$2.01M	Buy	+39,803	New	+$2.03M	0.16%	150
2015 Q3	–	Sell	-5,186	Closed	-$270K	–	542
2015 Q2	$270K	Buy	5,186 +320	+7%	+$18K	0.02%	377
2015 Q1	$281K	Hold	4,866	–	–	0.03%	341
2014 Q4	$260K	Buy	4,866 +1,176	+32%	+$65.8K	0.02%	469
2014 Q3	$212K	Sell	3,690 -138	-4%	-$8.46K	0.01%	575
2014 Q2	$300K	Buy	3,828 +234	+7%	+$15.8K	0.01%	525
2014 Q1	$200K	Buy	+3,594	New	+$243K	0.01%	425

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bluefin Capital Management's GSK Position: Q3 2022 in Review

Bluefin Capital Management sold out of GSK (GSK) in Q3 2022, closing a stake of 4,768 shares — an estimated $261K sold.

Bluefin Capital Management first reported a position in GSK in Q1 2014 and held it in 15 quarters. The position peaked at $2.01M in Q4 2015. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Bluefin Capital Management reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Bluefin Capital Management sold 4,768 GSK shares in Q3 2022, an estimated $261K.
Bluefin Capital Management first reported a position in GSK in Q1 2014 and held it in 15 quarters.
Bluefin Capital Management's GSK position peaked at $2.01M in Q4 2015.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Bluefin Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.